369
Participants
Start Date
November 30, 2012
Primary Completion Date
April 30, 2014
Study Completion Date
June 30, 2014
GLYX-13 5 mg/kg
Intravenous administration of 5 mg/kg into arm.
GLYX-13 10 mg/kg
Intravenous administration of 10 mg/kg into arm.
Placebo
Intravenous administration of normal saline into arm.
Clinilabs, Inc., New York
Michael R Liebowitz MD, New York
Finger Lake Clinical Research, Rochester
Lehigh Center for Clinical Research, Allentown
CRI Lifetree, Phildadelphia
PharmaSite Research , Inc., Baltimore
Atlanta Center for Medical Research, Atlanta
Atlanta Institute of Medicine and Research, Atlanta
Sarkis Clinical Trials, Gainesville
University of Alabama Office of Psychiatric Clinical Research, Birmingham
Indiana University Health Neuroscience Center, Indianapolis
Evanston Premier Healthcare Research, LLC, Northbrook
Chicago Research Center, Chicago
University of Kansas, Wichita
University of Texas Southwestern Medical Center of Dallas, Dallas
CRI Lifetree, Salt Lake City
Pacific Institute of Medical Research, Los Angeles
Pharmacology Research Institute, Los Alamitos
Pharmacology Research Institute, Encino
Artemis Institute for Clinical Research, San Diego
Pharmacology Research Institute, Newport Beach
Summit Research Network (Oregon), Inc., Portland
Summit Research Network, Seattle
Bostin Clinical Trials, Inc., Roslindale
CRI Lifetree, Marlton
Global Medical Institutes LLC, Princeton
Naurex, Inc, an affiliate of Allergan plc
INDUSTRY